Estrojel (estradiol) gel for local use 0.6 mg/g. 80 g. vial with dose №1

$47.00

Manufacturer: Belgium

Hypersensitivity to the active substance or to any of the excipients. Breast cancer (diagnosed, suspected, or in history). Diagnosed or suspected estrogen-dependent malignancies (such as endometrial cancer). Vaginal bleeding of unknown etiology. Untreated endometrial hyperplasia. Idiopathic venous thromboembolic diseases are present or have a history (for example, deep vein thrombosis (DVT), pulmonary embolism). Increased blood clotting was detected (for example, a deficiency of protein C, protein S, or antithrombin). Acute arterial thromboembolism is present or has recently been transferred (for example, angina, myocardial infarction). Acute liver diseases that are present or have a history (before normalization of laboratory parameters of liver function). Severe liver damage or impaired liver function with residual elevated levels of functional liver tests in the history. Porphyria.

Category:

Description

Estrojel Storage
active substance: estradiol (estradiol);

1 g of gel contains 0.6 mg of estradiol (as estradiol hemihydrate);

excipients: carbomer 980, triethanolamine, ethanol 96%, purified water.

Estrojel Dosage form
Gel for topical use.

Main physical and chemical properties: colorless transparent gel with the smell of alcohol.

Pharmacotherapeutic group
Gonadal hormones and drugs used in pathology of the genital area. Estrogens. Simple preparations of natural and semi-synthetic estrogens.

ATX code G03C A03.

Estrojel Pharmacological properties

Pharmacodynamics.

Estrogel belongs to the group of natural physiological estrogen. The active substance is chemically and biologically identical to endogenous human estradiol. Systematic application of 17β-estradiol by application to intact skin is possible. Estrogel corrects estrogen deficiency in menopausal or post-ovariectomy women and relieves menopausal symptoms. Estrogen prevents bone loss caused by menopause or ovariectomy.

When interacting with a specific receptor, estrogen forms a complex that mainly stimulates the synthesis of DNA and proteins at the intracellular level and has metabolic effects at the level of target organs. The most active estrogen at the receptor level is estradiol, which is mainly synthesized in the ovarian follicles during the period from menarche to menopause. Estrogel also has an estrogenic effect on the main target organs, acting not only on the ovaries, endometrium and mammary glands, but also on the hypothalamus, pituitary gland, vagina, uterus and liver. At the same time the effect similar to that usually takes place in a follicular phase of a cycle is observed.

Transdermal administration of Estrogel avoids the so-called effect of primary passage through the liver, which is the cause of increased synthesis of angiotensinogen, LDL lipoproteins (triglycerides) and some coagulation factors.

Indication
– Hormone replacement therapy (HRT) to correct estrogen deficiency and symptoms of estrogen deficiency, especially at age or artificial menopause: vasomotor disorders (hot flashes, night sweats), trophic disorders of the genitourinary tract (atrophic disorders, vulvovachinitis, diulvovaginitis) sleep, asthenia).

– Prevention of postmenopausal osteoporosis in women at high risk of fractures, women who do not tolerate other drugs approved for the prevention of osteoporosis, or for whom these drugs are contraindicated.

Experience with this therapy in women over 65 years of age is limited.

Contraindication
Hypersensitivity to the active substance or to any of the excipients.
Breast cancer (diagnosed, suspected or in the anamnesis).
Diagnosed or suspected estrogen-dependent malignancies (eg, endometrial cancer).
Vaginal bleeding of unknown etiology.
Untreated endometrial hyperplasia.
Idiopathic venous thromboembolic diseases present or in the anamnesis (for example deep vein thrombosis (DVT), pulmonary embolism).
Increased blood clotting (eg deficiency of protein C, protein S or antithrombin).
Acute arterial thromboembolism, present or recent (eg angina, myocardial infarction).
Acute liver disease, present or in the anamnesis (before the normalization of laboratory parameters of liver function).
There are severe liver damage or liver dysfunction with residual elevated levels of liver function tests in the anamnesis.
Porphyria.